Clinical Trial

Study of Aspirin in Patients With Vestibular Schwannoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2017-03-09; most recent amendment 2025-12-16.
Status change: Recruiting → Active, Not Recruiting 2025-12-16
Status change: Not Yet Recruiting → Recruiting 2018-07-09
Trial Details
NCT Number NCT03079999
Lead Sponsor Massachusetts Eye and Ear Infirmary
Collaborators: United States Department of Defense
Conditions Vestibular Schwannoma, Acoustic Neuroma, Neurofibromatosis 2
Enrollment 97 participants
Start Date 2018-06-11
Primary Completion 2026-08 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2025-12-18